Cargando…

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared two TPV/r dose combinations versus ritonavir-boosted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, David A., Cordery, Damien V., Zajdenverg, Roberto, Ruxrungtham, Kiat, Arastéh, Keikawus, Bergmann, Frank, Neto, José L. de Andrade, Scherer, Joseph, Chaves, Ricardo L., Robinson, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701182/ https://www.ncbi.nlm.nih.gov/pubmed/26730818 http://dx.doi.org/10.1371/journal.pone.0144917

Ejemplares similares

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
por: Jackson, AGA, et al.
Publicado: (2010)

Development and Palatability Assessment of Norvir(®) (Ritonavir) 100 mg Powder for Pediatric Population
por: Morris, John B., et al.
Publicado: (2019)

Brand versus generic dispensing trend for ciprofloxacin 500 mg, levofloxacin 500 mg, and moxifloxacin 400 mg (oral dosage forms) among pharmacies of Karachi, Pakistan
por: Zehra, Fatima, et al.
Publicado: (2017)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2021)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

Interchangeability of Two 500 Mg Amoxicillin Capsules with One 1000 Mg Amoxicillin Tablet After a Single Oral Administration
por: Zaid, A. N., et al.
Publicado: (2010)

Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?
por: Sardana, Kabir, et al.
Publicado: (2017)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
por: Arastéh, K, et al.
Publicado: (2010)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
por: Zorrilla, CD, et al.
Publicado: (2014)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
por: Robertson, John FR, et al.
Publicado: (2013)

Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
por: AlSwayeh, Reem, et al.
Publicado: (2021)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
por: Ouedraogo, Henri Gautier, et al.
Publicado: (2020)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2023)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_8qhp8mbfoc508oevitcdj69on8